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Abstract
Leukotrienes, one of the mediators of inflammation in asthma, have a strong bronchocon-
strictive effect. L-carnitine has been reported to influence respiratory functions. It has also been
reported that L-carnitine inhibits leukotriene synthesis. To evaluate the effects of L-carnitine on
oxygen saturation, urine leukotriene E4 levels and lung histopathology in a murine model of
asthma, high IgE responder BALB/c mice (n = 24) were systemically sensitized to ovalbumin
and chronically challenged with low particle mass concentrations of aerosolized ovalbumin, and
then they were divided into 3 groups (study groups A, B, and C) each including eight mice. After
methacholine-induced bronchoconstriction, the mice in groups A and B were given intraperitoneal
L-carnitine (250 and 125 mg/kg, respectively), while the mice in group C were given placebo.
Oxygen saturation of the mice was measured by pulse oxymeter before and after methacholine
and after L-carnitine/ placebo application. In addition, urine leukotriene E4 levels were measured
before asthma development, and 24-h after L-carnitine injection in asthmatic mice. Inflammation
in the lung tissues of the sacrificed animals was scored histopathologically to determine the effect
of L-carnitine on tissue level. A control group of non-sensitized mice (n = 8) treated with placebo
only was used for comparison of urine leukotriene E4 levels and of histopathological parameters.
Oxygen saturation of the mice in the study groups tended to decrease after methacholine and to
improve after L-carnitine injection, although these changes were not significant at all time points.
Urine leukotriene E4 levels of all 3 study groups increased significantly after asthma development.
The rate of increment was smallest in the group given the highest L-carnitine dose (group A). In-
flammation at the tissue level was also mildest in group A, and severest in the group that was not
given carnitine (group C). All of the study groups and the control group differed significantly with
respect to inflammation scores. In conclusion, L-carnitine improved oxygen saturation, and de-
creased urine leukotriene E4 levels and inflammation in lung tissues in the present murine model
of asthma.
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Leukotrienes, one of the mediators of inﬂammation in asthma, have a strong bronchoconstrictive eﬀect. L-carnitine has been reported to inﬂuence respiratory functions. It has also been reported that L-carnitine inhibits leukotriene synthesis. To evaluate the eﬀects of L-carnitine on oxygen saturation, urine leukotriene E4 levels and lung histopathology in a murine model of asthma, high IgE responder BALB/c mice (n＝24) were systemically sensitized to ovalbumin and chronically challenged with low particle mass concentrations of aerosolized ovalbumin, and then they were divided into 3 groups(study groups A, B, and C)each including eight mice. After methacholine-
induced bronchoconstriction, the mice in groups A and B were given intraperitoneal L-carnitine
(250 and 125 mg/kg, respectively), while the mice in group C were given placebo. Oxygen saturation of the mice was measured by pulse oxymeter before and after methacholine and after L-carnitine/
placebo application. In addition, urine leukotriene E4 levels were measured before asthma develop-
ment, and 24-h after L-carnitine injection in asthmatic mice. Inﬂammation in the lung tissues of the sacriﬁced animals was scored histopathologically to determine the effect o
 
g
 
L-carnitine on tissue level. A control group of non-sensitized mice (n＝8) treated with placebo only was used for comparison of urine leukotriene E4 levels and of histopathological parameters. Oxygen saturation of the mice in the study groups tended to decrease after methacholine and to improve after L-carnitine injection, although these changes were not signiﬁcant at all time points. Urine leukotriene E4 levels of all 3 study groups increased signiﬁcantly after asthma development. The rate of increment was smallest in the group given the highest L-carnitine dose(group A). Inﬂammation at the tissue level was also mildest in group A, and severest in the group that was not given carnitine
(group C). All of the study
 
s
 
roups and the control group diﬀered signiﬁcantly with respect to inﬂammation scores. In conclusion, L-carnitine improved oxygen saturation, and decreased urine leukotriene E4 levels and inﬂammation in lung tissues in the present murine model of asthma.
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A sthma is a chronic inﬂammatory di
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ease of the airways［1］. Various endogenous mediators play a role in inﬂammation. Leukotrienes are among the mediators which are synthesized in the bronchial mucosa by eosinophi  c s, basophils and mast  k ells. Leu  i otr  s ene
 
s
 
Copyright?ｃ2002 by Okayama University Medical School.
Original Article
 
Acta Med. Okayama, 2002 Vol. 56, No. 6, pp. 29 5-301
 
http://www.lib.okayama-u.ac.jp/www/acta/
Received October 26,2001;accepted July 10,2002.
?Corresponding author.Phone:＋90-232-2595959;Fax:＋90-232-2599723 E-mail:nuzuner＠deu.edu.tr(N.Uzuner)
1
Uzuner et al.: The role of L-carnitine in treatment of a murine model of
Produced by The Berkeley Electronic Press, 2002
play a very important role in asthma pathogenesis, and are involved in eosinophilic inﬂammation, bronchocon-
striction and edema formation［2］.
L-carnitine has been reported to improve the obstruc-
tive findings in pulmonary function tests in children undergoing chronic hemodialysis［3］. It has also been reported that L-carnitine decreases leukotriene synthesis by inactivation of lipoxygenase in hemodialysis patients
［4］. We previously evaluated the bronchodilator eﬀect of L-carnitine in tracheal and bronchial smooth muscle of Guinea pigs and in human bronchial smooth muscle in vitro, but observed no signiﬁcant eﬀects. However, since these tissues were taken from healthy subjects without asthma, this lack of signiﬁcance does not exclude a possible relation between asthma and L-carnitine［5］.
The aim of this study was to evaluate the eﬀects of L-carnitine on arterial oxygen saturation (SaO?), urine leukotriene E4(LTE4)levels, and lung histopathology in a murine model of asthma.
Materials and Methods
 
BALB/c mice with 87  homogeneity were used for the experiment. The mice were 8- to 10-weeks-old and weighed 28-30 g.
They were kept in hygienic macrolane cages and in air-conditioned rooms under a 12-h light/12-h dark cycle.
Thirty-two mice were divided into 4 groups, the study groups A, B, C and the control group, each including eight mice. The study was approved by the local ethical committee(00/09-02).
BALB/c mice are high IgE responders to ovalbumin［6］.
The mice in the study groups A, B, and C were sensitized by intraperitoneal injection of 10μg of alum precipitated chicken egg ovalbumin (grade V, 98 pure, Sigma, St. Louis, MO, USA)21 and 7 days before inhalational exposure. The mice in the control group were given saline solution by the same route and dosage.
The mice in the study groups were then exposed to aerosolized ovalbumin for 30 min per day on 3 days of the week up to 8 weeks［6］. Exposures were carried out in a whole body inhalation exposure system. Temperature and relative humidity were maintained at 20-25°C and 40-
60 , respectively. A solution of 2.5  ovalbumin in normal saline was aerosolized by delivery of compressed air to a sidestream jet nebulizer and injected into a
 
chamber. The aerosol generated by this nebulizer com-
prised  80  particles with a diameter of  4μm.
Particle concentration was maintained in the range of 10-
20 mg/m?. The mice in the control group were exposed to saline inhalation by the same system.
Mice with experimentally induced chronic asthma in the study groups A, B and C were given 3 doses of methacholine (at 6.25-12.5 and 25.0 mg/ml concentrations)for 3 min by the same system used for administration of aerosolized ovalbumin［7］. The time interval between the methacholine doses was 1h. SaO?
was measured by pulse oxymeter just before(0 min)and 5 min after each dose of methacholine. After that, while intraperitoneal L-carnitine was given at 250 mg/kg and 125 mg/kg to the mice in groups A and B, respectively,
the mice in group C were not given L-carnitine. Instead,
isotonic saline as placebo was injected by the same route to the animals in group C［8］. A third measurement of SaO?was also obtained 15 min after L-carnitine/placebo administration in these 3 study groups.
The control group of mice without asthma were not treated with either methacholine or carnitine. Thus, the responses to methacholine and carnitine, as determined by SaO?, were compared among the 3 study groups of asthmatic mice.
?
Twenty four-hour urine samples of the asthmatic mice in the study groups were collected twice, once before the induction of asthma and once after L-carnitine administra-
tion, by using metabolic cages. Similarly, 24-h urine samples of the control mice were collected at the begin-
ning of the study and just before sacrifice. The samples were separated into 2 aliquots. The first aliquot was used to measure urinary creatinine levels as the concentration of picric acid complex in alkaline media using a routine spectrophotometric method (Hitachi 911 autoanalyzer;
Hitachi, Tokyo, Japan). The second aliquot was sup-
plemented with 6N hydrochloric acid in order to acidify the urine to pH 3 for measurement of LTE4, then stored at－70°C till analysis. Urine samples were puriﬁed using C? reverse phase cartridges (500 mg/8.0 ml) (Altech Associates, Inc.2051 Waukegan Road, Deerﬁeld, IL,
USA). During puriﬁcation the samples were traced with tritium-labeled LTE4(［?H］-LTE4)(Dupont-NE, Bos-
ton, MA, USA)with the aim of calculating the recovery factor for LTE4［9, 10］. In puriﬁed samples LTE4 levels were determined using an LTE4 EIA (Enzyme
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Immunoassay) kit (Cayman Chemical Company, Ann Arbor, MI, USA). The results were expressed as pg LTE4/mg creatinine in urine.
The mice in the study groups were sacriﬁced 24-h after the last dose of carnitine/placebo. Control mice were sacriﬁced at the same time as the experimental mice. The trachea and lungs of the mice were inﬂated with 10  buﬀered forma-
lin, and after ﬁxation overnight, a horizontal slice was obtained from the left lung. The slices were embedded in paraﬃn, sectioned into 5-μm thick sections, and stained with hematoxylin-eosin. The degree of bronchial inﬂam-
mation was evaluated semi-quantitatively using scores of 0-3 to indicate no, mild, moderate, and severe inﬂam-
mation［6, 11］. In addition, the distribution and inten-
sity of the following ﬁndings were recorded:1) bron-
choconstriction (epithelial shedding or undulation of the nuclei of bronchial epithelial cells);2) increase in the number of goblet cells;3)inﬁltration of inﬂammatory cells and ﬁbrin from vessels into the mucosal and submucosal area of the bronchus and peribronchial interstitium;and 4)hypertrophy and thickening of the smooth muscle cell layer. A score of 0 indicated normal histology and a score of 3 indicated the greatest degree of alteration from normal.
Paired t-test(for n 6)and Wilcoxon’s signed rank test(for n 5)were used for the comparison of SaO?before and after various methacholine dosages and after L-carnitine administration.
Levels of signiﬁcance was accepted as＜0.05. Urinary LTE4 levels were compared within each group at the beginning and at the end of the study by paired t-test(n 6)and Wilcoxon’s signed rank tests (n 5). Mean increase in LTE4 level was analyzed by one way ANOVA and post-hoc Duncan tests. Histopathological scores were compared among the four groups by Kruskal-
Wallis test. Advanced analyses of the groups were performed by Mann-Whitney U test after Bonferroni correction.
Results
 
A total of 4 mice, 1 in group A and 3 in group B,
died due to hypoxia during the study period.
SaO?measured before and after methacholine administra-
tion in all 3 study groups and after L-carnitine administra-
tion in groups A and B or placebo in group C are shown in Tables 1 to 3. SaO?was found to decrease after all methacholine doses in all 3 groups. However, the decrease in SaO?was not always statistically signiﬁcant.
On the other hand, SaO?had a tendency to increase after L-carnitine administration, and this increase was signiﬁ-
cant at the 250 mg/kg dose(in group A).
SaO?decreased signiﬁcantly after administration of a 6.25 mg/ml dose of methacholine(P＝0.014), while it increased signiﬁcantly after administration of 250 mg/kg L-carnitine in group A(P＝0.027)(Table 1). Similarly,
administration of 25 mg/ml methacholine or 250 mg/kg L-carnitine led to a signiﬁcant decrease(P＝0.014)and a signiﬁcant increase (P＝0.012) in SaO?, respectively
(Table 3).
In the case of group B, 6.25 mg/ml of methacholine decreased SaO?signiﬁcantly(P＝0.007)and 125 mg/kg of L-carnitine increased SaO?, but not signiﬁcantly(Table 1). Similar results were obtained in this group when the mice were given 12.5 and 25 mg/ml of methacholine
(Tables 2 and 3).
In group C, SaO?decreased at all doses of metha-
choline, but the decrease was only signiﬁcant after a dose of 6.25 mg/ml(Table 1, P＝0.034). However, SaO?
did not tend to increase after placebo administration
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Table 1  Oxygen saturation of the mice in groups A, B and C before and after methacholine(6.25 mg/ml)and after L-carnitine/placebo administration
 
SaO? 0 min(before methacholine)
5 min after methacholine  
15 min after L-carnitine/placebo?
Group A(n＝7) 86.87±10.43  64.25±19.08? 85.37±14.84?
Group B(n＝5) 89.57± 5.38  65.71±11.26? 71.16± 9.06 Group C(n＝8) 86.85± 6.36  81.28± 4.57? 80.71± 5.36
?, Group A and B were given 250 and 125 mg/kg L-carnitine, respectively;group C was given placebo.?, SaO?signiﬁcantly decreased after methacholine(P＝0.014);?, SaO?signiﬁcantly increased after L-carnitine(P＝0.027);?, SaO?signiﬁcantly decreased after methacholine
(P＝0.007);?, SaO?signiﬁcantly decreased after methacholine(P＝0.034).
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(Tables 1-3).
? Intragroup evaluation revealed signiﬁcantly higher levels of urinary LTE4 after asthma development in all study groups
(Table 4). After that, the diﬀerence between the post-and pre-asthmatic urinary LTE4 levels was calculated for each group. The mean diﬀerences were 12.11±8.49, 17.32±
11.02, 44.32±06.12 and 8.59±2.59 pg LTE4/mg creatinine in groups A, B, C and the control group,
respectively. When all 4 groups were analyzed with respect to these diﬀerences, group C had statistically signiﬁcantly higher levels compared to the others (P＝
0.000).
The mean scores with respect to bronchial inﬂammation were 1.14±
0.37, 1.75±0.88, 1.77±0.75 and 0.33±0.5 in groups A, B, C and the control group, respectively. The intergroup variation was signiﬁcant(P＝0.005). In post-
hoc analyses, the control group was found to be signiﬁcantly diﬀerent from groups B and C, but not from group A(P＝0.008, P＝0.008 and P＝0.035, respec-
tively).
Lung sections in group A mice revealed mild inﬂammation in peribronchial and perivascular areas. In addition, there was mild constriction and thickening of the walls in a small number of bronchi (Fig. 1). Vascular
 
Table 2  Oxygen saturation of the mice in groups A, B and C before and after methacholine(12.5 mg/ml)and after L-carnitine/placebo administration
 
SaO? 0 min(before methacholine)
5 min after methacholine  
15 min after L-carnitine/placebo?
Group A(n＝7) 85.57±12.36  73.57±15.67  85.10± 3.60 Group B(n＝5) 87.00± 9.29  78.33± 9.77? 84.20±14.72 Group C(n＝8) 78.71±23.22  68.42±30.81  70.03±15.52
?, Group A and B were given 250 and 125 mg/kg L-carnitine, respectively;group C was given placebo.?, SaO?signiﬁcantly decreased after methacholine(P＝0.026).
Table 3  Oxygen saturation of the mice in groups A, B and C before and after methacholine (25 mg/ml)and after L-carnitine/placebo administration
 
SaO? 0 min(before methacholine)
5 min after methacholine  
15 min after L-carnitine/placebo?
Group A(n＝7) 85.01± 6.09  65.14±19.78? 84.57±11.70?
Group B(n＝5) 72.50± 9.29  75.75±10.78  79.25± 4.11 Group C(n＝8) 82.00±12.02  74.47±10.65  72.33± 9.48
?, Group A and B were given 250 and 125 mg/kg L-carnitine, respectively;group C was given placebo.?, SaO?signiﬁcantly decreased after methacholine(P＝0.014);?, SaO?signiﬁcantly increased after L-carnitine(P＝0.012).
Table 4  Pre-and post-asthmatic(after a 25 mg/ml dose of methacholine)urinary leukotriene E4 levels in mice
 
Urine Leukotriene E4 Levels (Mean±SD)
(pg LTE4/mg creatinine)
Groups  Pre asthmatic  Post asthmatic(after L-carnitine)? P
 
A(n＝7) 0.64±0.52  12.75± 8.80  0.018 B(n＝5) 3.53±2.86  20.85±11.89  0.018 C(n＝8) 10.71±5.03  55.03±11.15  0.028 Control Group?(n＝8) 2.76±2.50  11.36± 3.73  0.042
?, The mice in group A were given 250 mg/kg L-carnitine, and those in group B were given 125 mg/kg of L-carnitine. The mice in group C and the control group were not given L-carnitine. ?, Urine LTE4 levels were studied at the beginning and end of the study in control group.
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 Fig.1  Peribronchial mild inﬂammation(H&E×100, group A).
Fig.3  Peribronchial intense inﬂammation and thickening of the bronchial walls (H&E×40, group C).
Fig.5  Thickening of and ﬁbrin deposition in the vessel walls, and perivascular mild inﬂammation(H&E×400, group C).
Fig.2  Peribronchial moderate inﬂammation(H&E×100, group B).
Fig.6  Mild focal peribronchial and perivascular inﬂammation(H&
E×40, control group).
Fig. 4  Bronchoconstriction and mild peribronchial inﬂammation
(H&E×40, group C).
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changes like thickening of vessel walls and ﬁbrin deposi-
tion were mild and present in a small number of vessels.
Bronchial inﬂammation was moderate in group B mice
(Fig. 2). Bronchoconstriction and perivascular inﬂam-
mation were also more pronounced in group B than in group A mice. Thickening of bronchial and vascular walls were not diﬀerent between these 2 groups.
Group C mice showed severe peribronchial inﬂammation, and the other histopathological changes,
including bronchoconstriction (Fig.3)and perivascular inﬂammation(Fig.4), were also more pronounced in this group. In addition, the vessel walls of group C mice showed thickening and ﬁbrin deposition(Fig.5). There were no histopathologic changes other than mild focal inﬂammation in the lung tissues of the control mice(Fig.
6). None of the groups showed any increase in the number of goblet cells.
Discussion
 
Leukotrienes, a product of the lipooxygenase path-
way, bind to the leukotrien receptors present in bronchial smooth muscle and are found in increased concentrations in the bronchoalveolar ﬂuid of asthmatic patients［12, 13,
14］.
In hemodialysis patients, the metabolism of ara-
chidonic acid has been shown to shift from the cycloox-
ygenase to the lipoxygenase pathway［4］. When L-
carnitine was administered to children undergoing hemodialysis, the obstructive pattern in respiratory func-
tions was shown to improve［3］. Carnitine was demon-
strated to prevent bronchospasm due to Cys LT by blocking the lipoxygenase pathway in these patients.
L-carnitine causes partial restoration of the depleted essential fatty acids(linoleic and linolenic acids)observed in untreated dialysis patients［4］. Although the mecha-
nism by which carnitine corrects these abnormalities is unclear, it has been shown that dietary sources of alpha-linolenic acid may have the capacity to inhibit the generation of leukotrienes by leucocytes in patients with asthma［15］. Thus, carnitine might act on leukotriene metabolism by altering the ratio of essential fatty acids.
In a previous in vitro study, we showed that L-
carnitine did not aﬀect bronchoconstriction caused by methacholine in guinea pig tracheal and bronchial smooth muscle, or in human bronchial smooth muscle. However,
since there was no asthma pathology in the smooth muscles in that study, it was speculated that L-carnitine
 
did not aﬀect the bronchial smooth muscles under physiologic conditions［5］.
We performed this study to investigate the eﬀects of L-carnitine on acute attacks in a chronic asthma model in mice, and whether leukotriene synthesis inhibition was involved in these eﬀects, if any. In this study, acute attacks were induced by methacholine after the chronic asthma model was developed, and the eﬀect of L-carnitine on SaO?, as an indirect indicator of bronchoconstriction,
during acute attacks was observed. In addition, the role of L-carnitine on leukotriene synthesis was evaluated by measuring urinary LTE4 levels. More over, the eﬀect of L-carnitine on acute attacks in chronic asthma was inves-
tigated at the tissue level.
Post-methacholine SaO?decreased, although not signiﬁcantly at all times, in the study groups(Tables 1-
3). This ﬁnding indicate indirectly that there is bronchial hyperreactivity and inﬂammation in these animals with acute bronchospasm. After L-carnitine administration,
SaO?increased signiﬁcantly in group A(given 250 mg/kg L-carnitine), but increased insigniﬁcantly in group B
(given 125 mg/kg L-carnitine). These ﬁndings show that higher doses of L-carnitine had a more pronounced bronchodilator eﬀect in this chronic murine asthma model.
LTE4 is the major metabolite of leukotriene metabo-
lism and is excreted in urine. While other leukotriene metabolites are rapidly metabolized in vivo, LTE4 is more stable. Thus, LTE4 levels are often used as a marker of in vivo leukotriene production［16］, as they were here. We measured urine LTE4 levels before the development of asthma and after L-carnitine administra-
tion in asthmatic mice. Ideally, we would also have measured LTE4 levels in asthmatic mice before carnitine treatment. Unfortunately, we were unable able to do this due to the limited materials for LTE4 measurement.
However, we found signiﬁcantly increased levels of urine LTE4 even after L-carnitine administration in asthmatic mice in all study groups. We then calculated the mean diﬀerences between the post-and pre-asthmatic urine LTE4 levels for each group. The control group showed the lowest diﬀerence (8.59±2.59 pg LTE4/mg creat-
inine), followed in increasing order by group A(12.11±
8.49), group B (17.32±11.02)and group C (44.32±
06.12). These ﬁndings indicated that L-carnitine treat-
ment decreased urinary LTE4 excretion, and suggested that L-carnitine might be eﬀective in reducing the inﬂammatory process in asthma.
There were statistically signiﬁcant diﬀerences among
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the 4 groups with respect to the intensity of bronchial inﬂammation. The lowest inﬂammatory scores were in the control group (0.33±0.5) and group A (1.14±0.37).
These 2 groups did not diﬀer signiﬁcantly. On the other hand, the scores in group B (1.75±0.88)and group C
(1.77±0.75)were signiﬁcantly diﬀerent from those in the control group. Peribronchial and perivascular inﬂam-
mation was signiﬁcantly lower in group A than in group B or group C, which had the highest scores. As such,
bronchoconstriction and thickening of bronchial walls were prominent in group C, but were present in only a small number of bronchi in group A. Likewise, thicken-
ing of vessel walls and ﬁbrin deposition were mild in group A and extensive in group C. These ﬁndings show that the histopathological changes of asthma were attenuated in the mice given L-carnitine(groups A and B),
and were particularly small in group A, which was given the higher dose of L-carnitine. These ﬁndings, in turn,
support our hypothesis that L-carnitine has bronchodilator and anti-inﬂammatory properties.
In conclusion, intraperitoneal administration followed by aerosolized ovalbumin resulted in asthma development in BALB/c mice, and while methacholine administration decreased SaO?, L-carnitine administration increased SaO?in these asthmatic mice. In addition, urinary LTE4 levels and histopathological injury scores were lower in the asthmatic mice given L-carnitine. These results suggest that L-carnitine might have a role in the treatment of experimentally induced asthma in mice. Additional,
larger-scale studies will be needed to conﬁrm the eﬀectiveness of L-carnitine on inhibition of leukotrienes.
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